For partners & principals at lean life-science funds

External scientific diligence that fits how you already buy help.

Before IC or syndicate close, we break the deal thesis into the claims that must be true, test each one against independent evidence, and hand back an inspectable memo — the same OpEx habit as a KOL call or specialist screen, with a clearer artifact.

Built for $25–75M funds and staffed angel groups. Priced like diligence consulting, not like a software seat or an SEO retainer.

Scope a diligence engagementSee how the method works
View a worked example →

Lean funds need written diligence without a full science desk

A Partner or Principal at a small life-science fund already spends on outside help. The gap is an inspectable artifact — claim-by-claim — before IC or syndicate close.

  • The claims that must be true for the check are never written down
  • KOL notes and ChatGPT briefs are hard to share or defend in IC
  • Comparator and CMC failure modes get discovered too late
  • Associates cannot cover every modality; mega-fund process is overkill
  • LPs and co-investors increasingly expect a documented diligence trail

What you walk into the meeting with

We test the claims behind a seed or spinout deal — support, refute, and gaps — and return a citation-backed memo your IC or syndicate can actually use.

Make the claims explicit

We decompose the thesis into the 5–8 claims your partners must believe to write the check.

Test them against evidence

Independent literature, trials, patents, and comparator history — scored support / partial / refute, with gaps named.

Walk into IC with an artifact

A human-reviewed, citation-backed memo and priority diligence questions — not a fluent AI essay or a call note.

Generic AI research dump

Summarizes sources into a confident narrative without testing whether the deal claims hold.

Structured claim-tested diligence

Explicit hypotheses, support/refute scoring, comparator failure context, financeability realism, human-reviewed conclusion.

Same budget line as the help you already buy

Most lean funds already expense external science help from the management company or deal OpEx — KOL conversations, IP screens, ad-hoc scientific review. BioticaBio is that line item with a structured method and a written, citation-backed deliverable.

Entry claim screens start in the low thousands when you need a narrow read fast.

A full diligence Snapshot for IC / syndicate close typically sits in the mid–high four to low five figures — in band with specialist scientific DD packages funds already buy.

Scope a diligence engagement

See what the output looks like

An anonymized example of claim testing turned into a citation-backed memo a Partner can bring to IC.

Example

Diligence Snapshot preview

Claim table, support/refute scores, contradictions, and an investor interpretation — from an anonymized real Snapshot that used independent literature and trial evidence.

View the example

Scope the next deal read

Tell us the investment question. We will recommend an entry claim screen or a full IC Snapshot — priced like the external diligence consulting you already approve.

Scope a diligence engagementEmail john@bioticabio.com